Tissue Regenix Group plc TSSNF OTC

Tissue Regenix Group plc (TSSNF) generated $-1.37M in operating cash flow for quarter ending 2024-06-30. After capital expenditures of $206.36K, free cash flow was $-1.57M.

Free cash flow margin was -12.1% of revenue. Cash conversion ratio was 4.86x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (43/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (10/100) — Cash conversion ratio was 4.86x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 41/100 with 1/7 criteria passed.